Latest research on Erlotinib

Erlotinib hydrochloride (trade name Tarceva, Genentech/OSIP, originally coded as OSI-774) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer. Similar to gefitinib, erlotinib specifically targets the epidermal growth factor receptor (EGFR) tyrosine kinase. It binds in a reversible fashion to the adenosine triphosphate (ATP) binding site of the receptor. Erlotinib has recently been shown to be a potent inhibitor of JAK2V617F activity. JAK2V617F is a mutant of tyrosine kinase JAK2, is found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. The study suggests that erlotinib may be used for treatment of JAK2V617F-positive PV and other myeloproliferative disorders.

Erlotinib indications

These results showed that Afatinib 10 µM completely inhibited the intracellular growth of T. gondii similar to the inhibitory effect of pyrimethamine 5 µM, whereas Erlotinib 50 µM and Sunitinib 10 µM did not inhibit the intracellular growth of the parasite. [source, 2016]
In addition, considering that icotinib has a molecular structure similar to that of Gefitinib and Erlotinib, apart from being more cost-effective than Gefitinib or Erlotinib in the People’s Republic of China, icotinib is also an alternative choice to treat patients with advanced NSCLC as a first-line treatment. [source, 2016]
The promising effect of Erlotinib was also seen in subgroups of patients with first-line treatment, second-line treatment, stage IIIB disease, stage IV disease, exon 19 deletion mutation, and L858R mutation in exon 21. [source, 2016]
For patients administrated with Erlotinib, CR/PR of extracranial disease predicted lower BM risk than effect evaluation of SD. [source, 2016]
Two small molecule inhibitors of EGFR (Erlotinib and Gefitinib) have been used extensively in clinical settings and have demonstrated marked effects in the treatment of patients with non-small cell lung cancer (NSCLC) with activating EGFR mutations (3,4). [source, 2016]
The Southwest Cancer Cooperative Group conducted a phase II clinical trial (SWOG 0127) and reported the effectiveness of Erlotinib for the treatment of gastroesophageal junction adenocarcinoma [28]. [source, 2016]
We could confirm that single agent treatment with Erlotinib could not effectively block phosphorylation of the AKT protein. [source, 2016]
Icotinib is a kind of EGFR-tyrosine kinase inhibitor (EGFR-TKI) that has shown effectiveness as therapy for advanced NSCLC with EGFR activating mutations, such as Erlotinib and Gefitinib. [source, 2016]
Yau et al15 reported that rash (70%), diarrhea (50%), and malaise (40%) were the most commonly encountered toxic effects, and they concluded that the combination of bevacizumab plus Erlotinib was well tolerated but had no activity in an unselected population with sorafenib-refractory advanced HCC. [source, 2016]
Docetaxel is considered more effective than Pemetrexed and Erlotinib for the second-line treatment of advanced or metastatic squamous NSCLC. [source, 2016]